ALTIMMUNE, INC. Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Tax
ALTIMMUNE, INC. (ALT) reported Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Tax of $1.08 million for the 3-month period ending 2018-06-30, per its 10-Q filed 2018-08-14.
Discontinued › Expense Statement › Income Tax
us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax · last filed 2018-08-14
- ALTIMMUNE, INC. other comprehensive income (loss), foreign currency translation adjustment, tax for the quarter ending 2018-06-30 was $1.08M.
- ALTIMMUNE, INC. other comprehensive income (loss), foreign currency translation adjustment, tax for the quarter ending 2018-03-31 was -$615.47K.
- ALTIMMUNE, INC. other comprehensive income (loss), foreign currency translation adjustment, tax for the quarter ending 2017-12-31 was -$5.86M, a 448.06% decline year-over-year.
- ALTIMMUNE, INC. other comprehensive income (loss), foreign currency translation adjustment, tax for the quarter ending 2017-09-30 was $1.03M, a 21.93% decline year-over-year.
- ALTIMMUNE, INC. other comprehensive income (loss), foreign currency translation adjustment, tax for fiscal 2017 was -$3.00M, a 144.05% decline from fiscal 2016.
- ALTIMMUNE, INC. other comprehensive income (loss), foreign currency translation adjustment, tax for fiscal 2016 was $6.81M.
| Period end | Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Tax 3 month | Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Tax 6 month | Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Tax 9 month | Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Tax 12 month |
|---|---|---|---|---|
| 2018-06-30 | $1.08M 10-Q · filed 2018-08-14 | $463.18K 10-Q · filed 2018-08-14 | -$5.40M derived: sum of 3 quarters · filed 2018-08-14 | -$4.37M derived: sum of 4 quarters · filed 2018-08-14 |
| 2018-03-31 | -$615.47K 10-Q · filed 2018-05-15 | -$6.48M derived: sum of 2 quarters · filed 2018-05-15 | -$5.45M derived: sum of 3 quarters · filed 2018-05-15 | -$6.71M derived: sum of 4 quarters · filed 2018-08-14 |
| 2017-12-31 | -$5.86M derived: 10-K 12 month − 10-Q 9 month · filed 2018-04-02 | -$4.83M derived: sum of 2 quarters · filed 2018-04-02 | -$6.09M derived: sum of 3 quarters · filed 2018-08-14 | -$3.00M 10-K · filed 2018-04-02 |
| 2017-09-30 | $1.03M 10-Q · filed 2017-11-09 | -$228.94K derived: sum of 2 quarters · filed 2018-08-14 | $2.86M 10-Q · filed 2017-11-09 | $875.60K derived: sum of 4 quarters · filed 2018-08-14 |
| 2017-06-30 | -$1.26M 10-Q · filed 2018-08-14 | -$1.84M 10-Q · filed 2018-08-14 | -$152.44K derived: sum of 3 quarters · filed 2018-08-14 | $1.16M derived: sum of 4 quarters · filed 2018-08-14 |
| 2017-03-31 | -$579.84K 10-Q · filed 2018-05-15 | $1.10M derived: sum of 2 quarters · filed 2018-05-15 | $2.42M derived: sum of 3 quarters · filed 2018-05-15 | $5.04M derived: sum of 4 quarters · filed 2018-05-15 |
| 2016-12-31 | $1.68M derived: 10-K 12 month − 10-Q 9 month · filed 2018-04-02 | $3.00M derived: sum of 2 quarters · filed 2018-04-02 | $5.62M derived: sum of 3 quarters · filed 2018-04-02 | $6.81M 10-K · filed 2018-04-02 |
| 2016-09-30 | $1.32M 10-Q · filed 2017-11-09 | $3.93M derived: sum of 2 quarters · filed 2017-11-09 | $5.12M 10-Q · filed 2017-11-09 | |
| 2016-06-30 | $2.61M 10-Q · filed 2017-08-14 | $3.80M 10-Q · filed 2017-08-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B |